In a new study, researchers from the Centre for Psychedelic Research at Imperial College London found that on average, people reported improvements across a range of areas of sexual function up to six months after their psychedelic experience, including their enjoyment of sex, sexual…

Big News as MAPS PBC Rebrands to Lykos Therapeutics; Closes $100m Series A Funding

lykospbc.com/2024/01/05/map…

Atai Life Sciences Invests $50 Million into Beckley Psytech.

The investment gives atai a 35.5% ownership share and exposure to Beckley's advanced trials.

globenewswire.com/news-release/2…

Microdose takes a look at the top psychedelic stories of 2023. Including:

- Australia Legalization
- Government Support for Psychedelics
- MindMed's Phase 2b LSD Trial
- Cybin's Phase 2 Trials for Depression
- MAPS New Drug Application With FDA

microdose.buzz/news/psychedel…

We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history

microdose.buzz/news/exploring…

Awakn signs global licensing agreement for exclusivity of proprietary S-ketamine oral film formulation $AWKN
awaknlifesciences.com/awakn-enters-g…

Terran Biosciences Receives FDA Clearance for MRI Scan Technology

Terran gets FDA approval for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI

microdose.buzz/news/terran-re…

Millions of people are moving away from alcohol and towards cannabis. While psychedelics will be a mostly medical renaissance (to begin with), this does show that people - and their wallets - are ready for something new...

Shrooms Helped Them Quit Booze and Fentanyl. Now They're Fighting for Legal Access.

Canadians are suing the federal government for medical access to psychedelic mushrooms.

vice.com/en/article/xgw…

Mydecine Receives Patent Allowance from USPTO for MYCO-005 Compound

finance.yahoo.com/news/mydecine-…

‘We don’t sell our way of life’: Indigenous peyote users and the companies trying to cash in

From The Guardian
theguardian.com/us-news/2023/d…

Welcome to Microdose's weekly roundup of psychedelic medicine news. Big news includes MAPS moving MDMA to final stages with the FDA, and MindMed's positive Phase 2b results.

microdose.buzz/news/psychedel…

Welcome to Microdose's weekly roundup of psychedelic medicine news.

Big news includes MAPS moving MDMA to final stages with the FDA, and MindMed's positive Phase 2b results. buff.ly/4apxsII

From Vox: Gul Dolen wants to harness psychedelics for healing

Dolen hopes “critical periods” created by psychedelics can help stroke patients.

vox.com/23919260/gul-d…

Last week, a bipartisan group of lawmakers added access for military veterans to psychedelic clinical trials for the treatment of PTSD to a major defense bill.

Yesterday the bill passed in the House.

microdose.buzz/news/us-congre…

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

The trial met its primary endpoint, with 50% clinical remission rate in the 100 µg dose group at Week 4. buff.ly/3RHzgW0

Same here, Lily Urmann!

In a recent interview with the Mindfulness Experience podcast, Keith Fiveson discussed the power of Kanna for conscious evolution. buff.ly/3RLt6EB

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

The trial met its primary endpoint, with 50% clinical remission rate in the 100 µg dose group at Week 4. buff.ly/3RHzgW0

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Trial met its primary endpoint, with 50% clinical remission rate in the 100 µg dose group at Week 4.

businesswire.com/news/home/2023…